- Home
- MATX vs AKRO Comparison
MATX vs AKRO Comparison
Compare MATX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATX
- AKRO
- Stock Information
- Founded
- MATX 1882
- AKRO 2017
- Country
- MATX United States
- AKRO United States
- Employees
- MATX N/A
- AKRO N/A
- Industry
- MATX Marine Transportation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MATX Consumer Discretionary
- AKRO Health Care
- Exchange
- MATX Nasdaq
- AKRO Nasdaq
- Market Cap
- MATX 4.2B
- AKRO 3.5B
- IPO Year
- MATX N/A
- AKRO 2019
- Fundamental
- Price
- MATX $131.18
- AKRO $38.64
- Analyst Decision
- MATX Buy
- AKRO Strong Buy
- Analyst Count
- MATX 4
- AKRO 9
- Target Price
- MATX $165.00
- AKRO $76.29
- AVG Volume (30 Days)
- MATX 410.0K
- AKRO 975.6K
- Earning Date
- MATX 04-29-2025
- AKRO 05-09-2025
- Dividend Yield
- MATX 1.04%
- AKRO N/A
- EPS Growth
- MATX 67.43
- AKRO N/A
- EPS
- MATX 13.93
- AKRO N/A
- Revenue
- MATX $3,421,800,000.00
- AKRO N/A
- Revenue This Year
- MATX $1.53
- AKRO N/A
- Revenue Next Year
- MATX N/A
- AKRO N/A
- P/E Ratio
- MATX $9.33
- AKRO N/A
- Revenue Growth
- MATX 10.57
- AKRO N/A
- 52 Week Low
- MATX $100.50
- AKRO $17.86
- 52 Week High
- MATX $169.12
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MATX 46.82
- AKRO 32.61
- Support Level
- MATX $124.00
- AKRO $41.84
- Resistance Level
- MATX $133.95
- AKRO $45.38
- Average True Range (ATR)
- MATX 3.21
- AKRO 2.05
- MACD
- MATX 0.26
- AKRO -0.60
- Stochastic Oscillator
- MATX 72.16
- AKRO 1.96
About MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The business segments of the company are Ocean Transportation which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific, and Logistics segment which offers long haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.